hydroxychloroquine, page-111

Slight problem.

"Dr" ... John Campbell is actually a retired A&E nurse, who has a PhD in............ "Nursing Studies"

Is he "infinitely more qualified" than the leader of the Oxford Uni Recovery Trial?

Peter Horby is a British medical doctor, epidemiologist, and Professor of Emerging Infectious Diseases and Global Health at the University of Oxford and chair of the UK government's New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG). He is the founder, and former director of the Oxford University Clinical Research Unit in Hanoi, Vietnam which was founded in 2006. In 2014, Horby established the Epidemic Research Group Oxford (ERGO). ERGO incorporates a number of international projects such as the European Commission funded PREPARE and the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). In 2016, Horby became chair of ISARIC.

Horby specialises in the design of control programmes against infectious diseases. He is the co-chief investigator of the RECOVERY Trial into drugs for COVID-19 (the largest clinical trial yet in the world) alongside Martin Landray.^[1][2][3] In June 2020, he gave a statement at 10 Downing Street alongside the Prime Minister and Chief Scientific Adviser announcing the first positive trial results of the first life-saving COVID-19 drug, Dexamethasone.^[4][5] He is the primary author on the published preliminary report.^[6]

Horby is one of the 23 attendees of the Scientific Advisory Group for Emergencies (SAGE) ^[7] He is the chair of the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG)

.